Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
BriaCell Therapeutics (BCTX) has added Memorial Sloan Kettering Cancer Center as a site in its ongoing pivotal Phase 3 Bria-IMT™ plus immune checkpoint inhibitor trial for metastatic breast cancer (NCT06072612).
The study now includes more than 80 active clinical sites across 15 U.S. states, including major centers such as Penn Medicine’s Abramson Cancer Center, Mayo Clinic, Northwestern University and Yale’s Smilow Cancer Hospital. The randomized Bria-ABC study compares the Bria-IMT combination with physician’s choice of treatment, with overall survival as the primary endpoint and an interim analysis planned after 144 deaths. The trial recently received a positive recommendation from an independent DSMB to continue, follows positive Phase 2 survival data presented at ASCO 2026, holds FDA Fast Track designation, and was highlighted in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.” MSK has institutional financial interests related to BriaCell.
BriaCell (Nasdaq: BCTX) reported that Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate, has passed a key genetic engineering milestone, moving the program toward potential clinical development. Bria-MEL+ is a cell-based, genetically modified, off-the-shelf cancer vaccine designed to harness a patient’s immune system against melanoma.
The approach uses a simple saliva test to HLA-match patients to one of several premanufactured cell lines, aiming to provide personalized treatment without individualized manufacturing. Bria-MEL+ builds on BriaCell’s Bria-OTS+™ platform and complements its pipeline, including Bria-IMT™ in a pivotal Phase 3 metastatic breast cancer trial, Bria-OTS™ in breast cancer, and Bria-PROS+™ in prostate cancer, which recently received FDA clearance to begin clinical evaluation. BriaCell has started development activities to support Bria-MEL+ production for potential clinical use.
BriaCell Therapeutics (Nasdaq: BCTX) received U.S. FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+™, enabling initiation of a Phase 1/2a clinical study in prostate cancer. Bria-PROS+ is a next-generation, personalized, off-the-shelf, cell-based immunotherapy designed to activate multiple components of the immune system.
According to BriaCell, preclinical data showed activation of adaptive and innate immune responses, including naïve T cells, dendritic cells and NK cells. In August 2025, the program was awarded a $2 million non-dilutive grant from the U.S. National Cancer Institute to support manufacturing and planned clinical evaluation.
BriaCell (Nasdaq: BCTX) announced that Sunnybrook’s Odette Cancer Centre in Toronto has joined its ongoing pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (NCT06072612). This is BriaCell’s first Canadian clinical site, adding to over 80 active U.S. sites across 15 states.
The randomized study compares the Bria-IMT combination to physician’s treatment of choice, with overall survival as the primary endpoint and an interim analysis planned after 144 patient deaths. According to BriaCell, the trial continues following a positive DSMB recommendation, builds on positive Phase 2 survival data presented at ASCO 2026, has FDA Fast Track designation, and was highlighted in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.”
BriaCell Therapeutics (Nasdaq: BCTX) announced a manufacturing arrangement with FUJIFILM Biotechnologies California, a cell-therapy CDMO, to provide capacity for the remainder of BriaCell’s pivotal Phase 3 study and potential future commercial supply of Bria-IMT, an off-the-shelf allogeneic cell therapy for metastatic breast cancer.
BriaCell Therapeutics (Nasdaq: BCTX) engaged Charles River Associates and Kaleio to support commercial strategy, market access evaluation, and brand planning for its lead candidate Bria-IMT in metastatic breast cancer. Bria-IMT is in an ongoing pivotal Phase 3 study and is not yet commercially approved.
BriaCell (Nasdaq:BCTX) signed a non-binding Memorandum of Understanding with Netherlands-based Uneedle to support scalable, intradermal administration of its lead Phase 3 candidate Bria-IMT for metastatic breast cancer.
The MoU plans commercial-scale production of Uneedle’s proprietary microneedle devices, already used in Bria-IMT’s pivotal Phase 3 study, contingent on future regulatory approvals.
BriaCell Therapeutics (Nasdaq:BCTX) closed a best-efforts offering of 1,449,300 common shares at $3.25 per share, for approximately $4.7 million in gross proceeds.
According to BriaCell, net proceeds will support working capital, general corporate purposes, and advancement of business objectives.
BriaCell (Nasdaq:BCTX) reported Phase 2 and ongoing Phase 3 data for its Bria-IMT™ + checkpoint inhibitor regimen in heavily pretreated metastatic breast cancer at ASCO 2026.
Phase 2 Phase 3–regimen patients showed median OS of 16.6 months, >55% 1‑year and >27% 2‑year survival, with favorable safety, preserved quality of life, and blood-based biomarker correlations with progression-free survival.
BriaCell Therapeutics (Nasdaq:BCTX) priced a best-efforts offering of 1,449,300 common shares at $3.25 per share, for expected gross proceeds of about $4.7 million before fees. Closing is expected on June 2, 2026, subject to customary conditions.
Net proceeds are intended for working capital, general corporate purposes, and advancing business objectives. ThinkEquity is sole placement agent. The offering uses BriaCell’s effective Form S-3 shelf registration.